瑞康医药: 关于回购公司股份的进展公告

Core Viewpoint - The company has approved a share repurchase plan to buy back its own shares using bank loans and its own funds, with a total amount between RMB 100 million and RMB 200 million, aimed at implementing an employee stock ownership plan [2] Group 1: Share Repurchase Plan - The company will repurchase shares through centralized bidding, with a maximum price of RMB 4.5 per share and a repurchase period of 12 months from the board's approval date [2] - The total amount allocated for the share repurchase will not be less than RMB 100 million and not exceed RMB 200 million [2] - The company has disclosed its share repurchase progress, having repurchased 20.446517 million shares, accounting for 1.36% of the total share capital, with a total transaction amount of RMB 60.3963 million [3] Group 2: Compliance and Regulations - The company is adhering to the relevant regulations regarding share repurchase, including the disclosure of repurchase progress within the first three trading days of each month [3] - The repurchase activities have been conducted in compliance with the Shenzhen Stock Exchange's self-regulatory guidelines [3] - The company will continue to implement the repurchase plan based on market conditions and will fulfill its information disclosure obligations as required by law [3]